DeepMed Research

ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine

Phase 1

Completed

Conditions: Migraine

Interventions: Drug: Ubrogepant
Drug: Galcanezumab
Drug: Erenumab

First Posted Date: 2019-11-27

Last Posted Date: 2021-03-10

Lead Sponsor: Allergan

Target Recruit Count: 40

Registration Number: NCT04179474

Locations: 🇺🇸
Spaulding, West Bend, Wisconsin, United States
🇺🇸
QPS, Springfield, Missouri, United States

CoolSculpting® the Upper Arms and Inner Thighs in Participants of Chinese Descent (XinCOOL)

Not Applicable

Completed

Conditions: Body Fat Disorder

Interventions: Device: CoolSculpting® System

First Posted Date: 2019-10-29

Last Posted Date: 2021-04-01

Lead Sponsor: Allergan

Target Recruit Count: 50

Registration Number: NCT04142450

Locations: 🇨🇦
Pacific Derm, Vancouver, British Columbia, Canada
🇨🇦
Vancouver Laser and Skin Care Clinic, Vancouver, British Columbia, Canada
🇨🇦
Project Skin MD, Vancouver, British Columbia, Canada

A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants

Phase 2

Completed

Conditions: Thyroid Disease
Euthyroid
Thyroid Gland
Thyroid Hormones
Hypothyroidism

Interventions: Drug: Armour® Thyroid
Drug: Levothyroxine

First Posted Date: 2019-10-11

Last Posted Date: 2024-06-05

Lead Sponsor: Allergan

Target Recruit Count: 284

Registration Number: NCT04124705

Locations: 🇺🇸
Sponsor Site /ID# 235853, Fort Lauderdale, Florida, United States
🇺🇸
Sponsor Site /ID# 236809, West Palm Beach, Florida, United States
🇺🇸
Sponsor Site /ID# 235032, Atlanta, Georgia, United States

and more 25 locations

Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation

Phase 2

Completed

Conditions: Functional Constipation

Interventions: Drug: Placebo
Drug: Linaclotide

First Posted Date: 2019-10-01

Last Posted Date: 2022-04-26

Lead Sponsor: Allergan

Target Recruit Count: 35

Registration Number: NCT04110145

Locations: 🇺🇸
HealthStar Research, Hot Springs, Arkansas, United States
🇺🇸
Foundation Pediatrics Med Clinical Research Partners, LLC, East Orange, New Jersey, United States
🇺🇸
David M. Headley, MD, P.A., Port Gibson, Mississippi, United States

and more 14 locations

AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

Phase 2

Completed

Conditions: Glabellar Lines

Interventions: Drug: Placebo
Drug: AGN-151586

First Posted Date: 2019-09-19

Last Posted Date: 2023-07-28

Lead Sponsor: Allergan

Target Recruit Count: 198

Registration Number: NCT04096326

Locations: 🇺🇸
DermResearch Inc. /ID# 234483, Austin, Texas, United States
🇺🇸
Austin Institute for Clinical Research /ID# 237135, Pflugerville, Texas, United States
🇺🇸
Center for Dermatology Clinical Research /ID# 237798, Fremont, California, United States

and more 6 locations

A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated

Phase 4

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Dexamethasone Intravitreal Implant

First Posted Date: 2019-05-17

Last Posted Date: 2022-10-07

Lead Sponsor: Allergan

Target Recruit Count: 82

Registration Number: NCT03953807

Locations: 🇵🇹
Chuc /Id# 233643, Coimbra, Portugal
🇵🇹
IRL - Instituto de Retina e Diabetes Ocular de Lisboa /ID# 233667, Lisbon, Portugal
🇵🇹
Hospital de Santo Andre /ID# 233670, Leiria, Portugal

and more 23 locations

Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

Phase 3

Completed

Conditions: Episodic Migraine

Interventions: Drug: Atogepant

First Posted Date: 2019-05-06

Last Posted Date: 2022-05-12

Lead Sponsor: Allergan

Target Recruit Count: 685

Registration Number: NCT03939312

Locations: 🇺🇸
Pediatric and Adolescent NeuroDevelopmental Associates (PANDA) Neurology, Atlanta, Georgia, United States
🇺🇸
Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States
🇺🇸
Neuro Pain Medical Center, Fresno, California, United States

and more 104 locations

BOTOX® for the Treatment of Platysma Prominence

Phase 2

Completed

Conditions: Platysma Prominence

Interventions: Drug: BOTOX® purified neurotoxin complex
Drug: Placebo

First Posted Date: 2019-04-16

Last Posted Date: 2023-05-03

Lead Sponsor: Allergan

Target Recruit Count: 171

Registration Number: NCT03915067

Locations: 🇺🇸
Dallas Plastic Surgery Institute /ID# 236528, Dallas, Texas, United States
🇨🇦
Sweat Clinics of Canada /ID# 236590, Toronto, Ontario, Canada
🇨🇦
Pacific Derm /ID# 238236, Vancouver, British Columbia, Canada

and more 9 locations

Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China

Phase 4

Completed

Conditions: Macular Edema
Retinal Vein Occlusion

Interventions: Drug: OZURDEX

First Posted Date: 2019-04-09

Last Posted Date: 2023-03-31

Lead Sponsor: Allergan

Target Recruit Count: 150

Registration Number: NCT03908307

Locations: 🇨🇳
The Eye and ENT Hospital Affiliated of Fudan Univesity /ID# 233666, Shanghai, China
🇨🇳
Peking Union Medical College Hospital /ID# 233616, Beijing, Beijing, China
🇨🇳
The First Xiangya Hospital of Central South University /ID# 233627, Changsha Hunan, China

and more 6 locations

International CoolSculpting: Study to Evaluate Patient Satisfaction for Non-Invasive Fat Reduction in Abdomen and/or Flanks (iCOOL)

Not Applicable

Completed

Conditions: Non-invasive Fat Reduction

Interventions: Device: CoolSculpting® System

First Posted Date: 2019-04-09

Last Posted Date: 2023-06-27

Lead Sponsor: Allergan

Target Recruit Count: 120

Registration Number: NCT03909100

Locations: 🇸🇬
Halley Medical Aesthetics, Singapore, Singapore
🇦🇺
Academy Face and Body, Subiaco, Western Australia, Australia
🇸🇬
Dr Benjamin Yim Clinical Aesthetics and Laser Centre, Singapore, Singapore

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy